Mechanisms of simple hepatic steatosis: Not so simple after all

Clinics in Liver Disease

Volumn 16, Issue 3, 2012, Pages 505-524

  Matherly, Scott C ^a   Puri, Puneet ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hepatic steatosis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Triglycerides

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADIPONECTIN; ADRENALIN; CARNITINE PALMITOYLTRANSFERASE I; CHYLOMICRON; DIACYLGLYCEROL; FATTY ACID; FATTY ACID SYNTHASE; GLUCOSE; GLYCOGEN; INFLIXIMAB; INSULIN; INTERLEUKIN 6; LIPOPROTEIN LIPASE; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MALONYL COENZYME A; MICRORNA 122; MICRORNA 124; MICRORNA 143; MICRORNA 375; NORADRENALIN; OLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; CARBOHYDRATE INTAKE; CELL DIFFERENTIATION; CELL MIGRATION; CYTOPLASM; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FATTY LIVER; FEEDING BEHAVIOR; FOOD INTAKE; GENE EXPRESSION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOLYSIS; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE FLORA; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LIPOTOXICITY; LIVER CIRRHOSIS; LIVER METABOLISM; METABOLIC SYNDROME X; MISSENSE MUTATION; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; RNA METABOLISM; RNA TRANSLATION; ROUX Y ANASTOMOSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THERMOGENESIS; WEIGHT REDUCTION;

ANIMALS; DIET; FATTY LIVER; FEMALE; GASTROINTESTINAL TRACT; GLUCOSE; HOMEOSTASIS; HUMANS; INFLAMMATION; INSULIN; MALE; MICE; RATS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84864090834     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.05.005     Document Type: Review

References (97)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
2. Mansbach C.M., Gorelick F. Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons. Am J Physiol Gastrointest Liver Physiol 2007, 293:G645-G650.
3. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
4. Macfarlane D.P., Forbes S., Walker B.R. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 2008, 197:189-204.
5. McGarry J.D., Mannaerts G.P., Foster D.W. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest 1977, 60:265-270.
6. Donnelly K.L., Smith C.I., Schwarzenberg S.J., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351.
7. Postic C., Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008, 118:829-838.
8. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004, 114:147-152.
9. Diraison F., Beylot M. Role of human liver lipogenesis and reesterification in triglycerides secretion and in FFA reesterification. Am J Physiol 1998, 274:E321-E327.
10. Araya J., Rodrigo R., Videla L.A., et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004, 106:635-643.
11. Puri P., Baillie R.A., Wiest M.M., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46:1081-1090.
12. Brown M.S., Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997, 89:331-340.
13. Horton J.D., Shah N.A., Warrington J.A., et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A 2003, 100:12027-12032.
14. Moon Y.A., Shah N.A., Mohapatra S., et al. Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins. J Biol Chem 2001, 276:45358-45366.
15. Gonzalez-Baro M.R., Lewin T.M., Coleman R.A. Regulation of triglyceride metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action. Am J Physiol Gastrointest Liver Physiol 2007, 292:G1195-G1199.
16. Sato R., Miyamoto W., Inoue J., et al. Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription. J Biol Chem 1999, 274:24714-24720.
17. Chakravarty K., Leahy P., Becard D., et al. Sterol regulatory element-binding protein-1c mimics the negative effect of insulin on phosphoenolpyruvate carboxykinase (GTP) gene transcription. J Biol Chem 2001, 276:34816-34823.
18. Shimomura I., Bashmakov Y., Horton J.D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 1999, 274:30028-30032.
19. Jump D.B. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol 2002, 13:155-164.
20. Yamashita H., Takenoshita M., Sakurai M., et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci U S A 2001, 98:9116-9121.
21. Kawaguchi T., Takenoshita M., Kabashima T., et al. Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/dephosphorylation of the carbohydrate response element binding protein. Proc Natl Acad Sci U S A 2001, 98:13710-13715.
22. Towle H.C. Glucose as a regulator of eukaryotic gene transcription. Trends Endocrinol Metab 2005, 16:489-494.
23. Iizuka K., Bruick R.K., Liang G., et al. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A 2004, 101:7281-7286.
24. Ma L., Robinson L.N., Towle H.C. ChREBP*Mlx is the principal mediator of glucose-induced gene expression in the liver. J Biol Chem 2006, 281:28721-28730.
25. Liu Y., Qiu de K., Ma X. Liver X receptors bridge hepatic lipid metabolism and inflammation. J Dig Dis 2012, 13:69-74.
26. Laplante M., Sabatini D.M. An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009, 19:R1046-R1052.
27. Repa J.J., Liang G., Ou J., et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000, 14:2819-2830.
28. Cha J.Y., Repa J.J. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 2007, 282:743-751.
29. Vacca M., Degirolamo C., Mariani-Costantini R., et al. Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley Interdiscip Rev Syst Biol Med 2011, 3:562-587.
30. Mitro N., Mak P.A., Vargas L., et al. The nuclear receptor LXR is a glucose sensor. Nature 2007, 445:219-223.
31. Wang Y.X. PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res 2010, 20:124-137.
32. Rogue A., Renaud M.P., Claude N., et al. Comparative gene expression profiles induced by PPARgamma and PPARalpha/gamma agonists in rat hepatocytes. Toxicol Appl Pharmacol 2011, 254:18-31.
33. Costet P., Legendre C., More J., et al. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 1998, 273:29577-29585.
34. Nissen S.E., Nicholls S.J., Wolski K., et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 2007, 297:1362-1373.
35. Barish G.D., Narkar V.A., Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006, 116:590-597.
36. Chao L., Marcus-Samuels B., Mason M.M., et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000, 106:1221-1228.
37. Krey G., Braissant O., L'Horset F., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997, 11:779-791.
38. Kim J.B., Wright H.M., Wright M., et al. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A 1998, 95:4333-4337.
39. Shulman A.I., Mangelsdorf D.J. Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med 2005, 353:604-615.
40. Maeda N., Takahashi M., Funahashi T., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094-2099.
41. Hardie D.G. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003, 144:5179-5183.
42. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174.
43. Kawaguchi T., Osatomi K., Yamashita H., et al. Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J Biol Chem 2002, 277:3829-3835.
44. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
45. Pagano G., Pacini G., Musso G., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002, 35:367-372.
46. Chitturi S., Abeygunasekera S., Farrell G.C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
47. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
48. Xu H., Barnes G.T., Yang Q., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
49. Ramos E.J., Xu Y., Romanova I., et al. Is obesity an inflammatory disease?. Surgery 2003, 134:329-335.
50. Maury E., Brichard S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010, 314:1-16.
51. Fain J.N., Bahouth S.W., Madan A.K. TNFalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 2004, 28:616-622.
52. Cawthorn W.P., Sethi J.K. TNF-alpha and adipocyte biology. FEBS Lett 2008, 582:117-131.
53. Sabio G., Das M., Mora A., et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
54. Hui J.M., Hodge A., Farrell G.C., et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004, 40:46-54.
55. Barbuio R., Milanski M., Bertolo M.B., et al. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 2007, 194:539-550.
56. Bastard J.P., Lagathu C., Caron M., et al. Point-counterpoint: interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007, 102:821-822. [author reply: 825].
57. Pedersen B.K., Fischer C.P. Physiological roles of muscle-derived interleukin-6 in response to exercise. Curr Opin Clin Nutr Metab Care 2007, 10:265-271.
58. Bruun J.M., Lihn A.S., Pedersen S.B., et al. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 2005, 90:2282-2289.
59. Kanda H., Tateya S., Tamori Y., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006, 116:1494-1505.
60. Alessi M.C., Poggi M., Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007, 18:240-245.
61. Ma L.J., Mao S.L., Taylor K.L., et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004, 53:336-346.
62. Yang Q., Graham T.E., Mody N., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
63. Wu H., Jia W., Bao Y., et al. Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008, 79:185-190.
64. Pagano C., Soardo G., Pilon C., et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006, 91:1081-1086.
65. Yamauchi T., Hara K., Kubota N., et al. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord 2003, 3:243-254.
66. Kadowaki T., Yamauchi T., Kubota N., et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
67. Ouchi N., Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007, 380:24-30.
68. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
69. Motoshima H., Wu X., Mahadev K., et al. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004, 315:264-271.
70. Matsubara M. Plasma adiponectin decrease in women with nonalcoholic fatty liver. Endocr J 2004, 51:587-593.
71. Xu A., Wang Y., Keshaw H., et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91-100.
72. Oral E.A., Simha V., Ruiz E., et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002, 346:570-578.
73. Swellam M., Hamdy N. Association of nonalcoholic fatty liver disease with a single nucleotide polymorphism on the gene encoding leptin receptor. IUBMB Life 2012, 64:180-186.
74. Lewis G.F., Carpentier A., Adeli K., et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002, 23:201-229.
75. Wolfrum C., Stoffel M. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab 2006, 3:99-110.
76. Wolfrum C., Asilmaz E., Luca E., et al. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 2004, 432:1027-1032.
77. Kabir M., Catalano K.J., Ananthnarayan S., et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 2005, 288:E454-E461.
78. Samuel V.T., Liu Z.X., Qu X., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004, 279:32345-32353.
79. Brown M.S., Goldstein J.L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 2008, 7:95-96.
80. Schwimmer J.B., Celedon M.A., Lavine J.E., et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009, 136:1585-1592.
81. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
82. Petersen K.F., Dufour S., Feng J., et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 2006, 103:18273-18277.
83. Speliotes E.K., Butler J.L., Palmer C.D., et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010, 52:904-912.
84. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461-1465.
85. Huang Y., He S., Li J.Z., et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A 2010, 107:7892-7897.
86. He S., McPhaul C., Li J.Z., et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010, 285:6706-6715.
87. Osei-Hyiaman D., DePetrillo M., Pacher P., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298-1305.
88. Tam J., Liu J., Mukhopadhyay B., et al. Endocannabinoids in liver disease. Hepatology 2011, 53:346-355.
89. Lustig R.H. Fructose: metabolic, hedonic, and societal parallels with ethanol. J Am Diet Assoc 2010, 110:1307-1321.
90. Stanhope K.L., Schwarz J.M., Keim N.L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009, 119:1322-1334.
91. Huang D., Dhawan T., Young S., et al. Fructose impairs glucose-induced hepatic triglyceride synthesis. Lipids Health Dis 2011, 10:20.
92. Cheung O., Puri P., Eicken C., et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008, 48:1810-1820.
93. Rottiers V., Naar A.M. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012, 13:1.
94. Backhed F., Ding H., Wang T., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004, 101:15718-15723.
95. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009, 48:1-26.
96. Turnbaugh P.J., Ley R.E., Mahowald M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
97. Greiner T., Backhed F. Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol Metab 2011, 22:117-123.